Abstract
The purpose of this TriMark Publications report is to describe the specific market segment of the in vitro diagnostics market called point of care testing (POCT). It examines these clinical measurement devices and their reagents and supplies as utilized in hospitals, clinics and doctor' s offices. An analysis of analytes that are related to the common chemical constituents of blood, plasma or serum at the point of care of the patient is addressed. Moreover, the study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories. Additionally, rapid detection of food pathogens and infectious pathogens (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company' s market position.
Table of Contents
- 1. Overview
- 1.1 About this Report
- 1.2 Scope of the Report
- 1.3 Objectives
- 1.4 Methodology
- 1.5 Executive Summary
- 2. Overview of Diagnostic Testing Point of Care
- 2.1 POCT Testing Sites
- 2.2 POCT Market Structure
- 2.3 New Directions in Clinical IVD Testing
- 3. POC and Rapid Testing Market Analysis: Size, Background Analysis,
Growth, Share and Competitors
- 3.1 Global POCT Market
- 3.2 U.S. POCT Market
- 3.3 European POCT Market
- 3.3.1 German Point of Care Diagnostic Market
- 3.3.2 U.K. POCT Diagnostic Market
- 3.3.2.1 U.K. POC Market Statistics
- 3.3.2.2 U.K. Competitive Analysis
- 3.3.2.3 U.K. Market Access
- 3.3.3 French Point of Care Diagnostic Market
- 3.3.4 Italian POC Diagnostic Market
- 3.3.5 Spanish POC Diagnostic Market
- 3.3.6 Scandinavian Point of Care Market
- 3.3.7 Swedish POCT Market
- 3.3.8 Finland POCT Market
- 3.3.9 Norway POCT Market
- 3.3.10 Swiss POCT Market
- 3.3.11 Dutch Clinical Laboratory Diagnostic Market
- 3.3.12 Belgian Clinical Laboratory Diagnostic Market
- 3.3.13 Portugal Clinical Laboratory Diagnostic Market
- 3.3.14 Austria Clinical Laboratory Diagnostic Market
- 3.3.15 Greek Clinical Laboratory Diagnostic Market
- 3.3.16 Poland Clinical Laboratory Diagnostic Market
- 3.3.17 Czech Republic Clinical Laboratory Diagnostic Market
- 3.3.18 Turkish Point of Care Market
- 3.4 Asian POCT Markets
- 3.4.1 Japanese POCT Market
- 3.4.2 Indian POCT Market
- 3.4.3 Chinese Point of Care Market
- 3.5 Rest of the World POCT Market
- 3.5.1 Canada Point of Care Market
- 3.5.2 Brazil Point of Care Market
- 3.5.3 Australia Point of Care Market
- 3.6 Overview of Asian Healthcare Market
- 3.6.1 Singapore
- 3.6.2 Malaysia
- 3.6.3 Thailand
- 3.6.4 Indonesia
- 3.6.5 Philippines
- 3.6.6 South Korea
- 3.6.7 Taiwan
- 4. POCT Individual Markets
- 4.1 Glucose Testing
- 4.2 POCT Individual Market Sectors, Size, Growth Rates and Competitors
- 4.2.1 World Market
- 4.2.2 U.S. Market
- 4.2.3 European Market
- 4.2.3 Alternate Glucose Monitoring Products
- 4.2.4 HbA1c POCT
- 4.3 Blood Gas and Electrolytes
- 4.3.1 Whole Blood Lactate
- 4.4 Rapid Coagulation Tests
- 4.4.1 World POCT Coagulation Market
- 4.4.2 U.S. Coagulation Market
- 4.4.2 European Coagulation Market
- 4.5 Rapid Cardiac Markers
- 4.5.1 U.S. Market
- 4.5.2 European Market
- 4.6 Drugs of Abuse Screening Testing
- 4.6.1 Acetaminophen
- 4.6.2 Tricyclic Antidepressants (TCAs)
- 4.6.3 Other Toxic Drugs
- 4.6.4 Drug Testing Selectivity
- 4.6.5 Methaqualone and Phencyclidine (PCP)
- 4.6.6 Tetrahydrocannabinol
- 4.6.7 Drug Panels by Toxidromes
- 4.6.8 Alcohol Testing
- 4.7 Urine Strips
- 4.8 Pregnancy Tests
- 4.9 Fecal Occult Blood
- 4.10 Hemoglobin Testing
- 4.11 Miscellaneous Rapid Tests
- 4.11.1 Estriol
- 4.11.2 Fetal Fibronectin (fFN)
- 4.11.3 H. pylori
- 4.11.4 Vaginal pH and Vaginitis
- 4.11.5 Bladder Cancer
- 4.11.6 Fetal Status
- 4.12 Human Immunodeficiency Virus (HIV)
- 4.13 Cholesterol
- 4.14 Infectious Disease
- 4.14.1 C. difficile
- 4.14.2 Giardia
- 4.14.3 Salmonella and Campylobacter
- 4.14.4 Malaria Testing
- 4.14.5 Influenza Testing
- 4.14.6 Strep Testing
- 4.14.7 Chlamydia
- 4.14.8 Mononucleosis
- 4.14.9 Rubella
- 4.14.10 Staphylococcus Aureus
- 4.14.11 Hepatitis
- 4.14.12 Gonorrhea
- 4.14.13 Tuberculosis (TB)
- 4.14.14 Herpes Simplex Virus Type-2
- 4.15 Infant Jaundice
- 4.16 Anthrax
- 4.15 Rupture of Fetal Membranes (ROM)
- 4.16 Food Pathogens
- 4.17 Typhoid
- 5. POCT: Reagents and Equipment
- 5.1 Blood Glucose Monitoring
- 5.1.1 LifeScan
- 5.1.2 Roche Accu-Chek
- 5.1.3 Siemens
- 5.1.4 Cholestech
- 5.1.5 Medisense (Abbott)
- 5.1.6 International Technidyne Corporation
- 5.1.7 HemoCue
- 5.1.8 GDS Technology
- 5.1.9 LXN Corporation
- 5.1.10 Medtronic MiniMed
- 5.1.11 Cygnus
- 5.1.12 Abaxis
- 5.1.13 Inverness Medical Technology
- 5.2 Blood Gas and Electrolytes
- 5.2.1 Optical Sensors, Inc.
- 5.2.2 Roche Corporation
- 5.2.3 TechnoMedica
- 5.2.4 Siemens
- 5.2.5 Instrumentation Laboratory
- 5.2.6 Nova Biomedical
- 5.2.7 Radiometer
- 5.2.8 Abbott (i-STAT Corporation)
- 5.2.9 Span Diagnostics
- 5.2.10 Avox Systems
- 5.2.11 Disetronic Medical Systems
- 5.2.12 Nova
- 5.2.13 ITC
- 5.2.14 Osmetech
- 5.3 Rapid Coagulation Tests
- 5.3.1 POC Coagulation Instrument Description
- 5.3.1.1 Roche Diagnostics Corp.
- 5.3.1.2 Abbott (i-STAT Corp.)
- 5.3.1.3 International Technidyne Corp.
- 5.3.1.4 Medtronic Cardiac Surgery
- 5.3.1.5 HemoSense
- 5.3.1.6 Helena Point of Care
- 5.3.1.7 Siemens
- 5.3.1.8 Beckman Coulter
- 5.3.1.9 Pharmanetics (Cardiovascular Diagnostics)
- 5.3.1.10 Sienco
- 5.3.1.11 Accumetrics
- 5.3.2 Connectivity Issues
- 5.3.3 Cost Benefits
- 5.3.4 Quality Control Issues
- 5.3.5 Certification for POC Coagulation Devices
- 5.3.1 POC Coagulation Instrument Description
- 5.4 Rapid Cardiac Markers
- 5.4.1 Spectral Diagnostics
- 5.4.2 Biosite Diagnostics
- 5.4.3 Roche Diagnostics
- 5.4.4 First Medical
- 5.4.5 Ani Biotech
- 5.4.6 Response Biomedical
- 5.4.7 Dade Behring
- 5.4.8 SYNX Pharma, Inc.
- 5.4.9 Ark Therapeutics, Ltd.
- 5.4.10 Abbott (i-STAT Corp.)
- 5.4.11 LifeSign
- 5.4.12 Mitsubishi Kagaku Iatron
- 5.5 Rapid Drugs of Abuse
- 5.5.1 Biosite Diagnostics (Inverness)
- 5.5.2 Abbott Diagnostics
- 5.5.3 Roche Diagnostics
- 5.5.4 BioScan Screening Systems, Inc.
- 5.5.5 American Bio Medica Corp.
- 5.5.6 Pharmatech Corporation
- 5.5.7 Worldwide Medical
- 5.5.8 Syva Dade Behring
- 5.5.9 STC Technologies, Inc.
- 5.5.10 DynaGen, Inc.
- 5.5.11 OraSure
- 5.5.12 LifePoint
- 5.5.13 Avitar, Inc.
- 5.5.14 Cozart Biosciences
- 5.5.15 Securetec
- 5.6 Urine Strips
- 5.7 Rapid Pregnancy and Fertility Tests
- 5.8 Fecal Occult Blood
- 5.8.1 Helena Laboratories
- 5.8.2 Biomerica
- 5.8.3 Beckman Coulter
- 5.8.4 Wampole Laboratories
- 5.8.5 Worldwide Medical
- 5.8.6 Aerscher Diagnostics
- 5.8.7 Enterix
- 5.8.8 Medix Biochemica
- 5.9 Hemoglobin Testing
- 5.9.1 Wampole Laboratories
- 5.9.2 HemoCue, Inc.
- 5.9.3 Micro Diagnostics Corporation
- 5.9.4 GDS Technology
- 5.10 Miscellaneous Rapid Tests
- 5.10.1 Triage C. difficile Panel
- 5.10.2 Ketoacids
- 5.10.3 Acetaminophen
- 5.10.4 Estriol
- 5.10.5 H. pylori
- 5.10.6 Vaginal Fluid pH and Vaginitis
- 5.10.7 Prostate Specific Antigen (PSA)
- 5.10.8 Bladder Cancer
- 5.10.9 Other Rapid Cancer Tests
- 5.10.10 Fetal Status (PROM)
- 5.10.11 Osteoporosis
- 5.11 HIV
- 5.12 Cholesterol
- 5.12.1 Cholestech
- 5.12.2 Lifestream Technologies, Inc.
- 5.12.3 Actimed Laboratories
- 5.12.4 StatSite Meter
- 5.12.5 Polymer Technology Systems
- 5.12.6 International Medical Innovations Inc. (IMI)
- 5.13 Infectious Disease
- 5.13.1 C. difficile
- 5.13.2 Giardia
- 5.13.3 Dengue Fever
- 5.13.4 Malaria Testing
- 5.13.5 Rapid Influenza Testing
- 5.13.6 Streptococcus Testing
- 5.13.7 Chlamydia
- 5.13.8 Mononucleosis
- 5.13.9 Rubella
- 5.13.10 Staphylococcus Aureus
- 5.13.11 Hepatitis
- 5.13.12 E. coli O157
- 5.13.13 Gonorrhea Testing
- 5.13.14 Smallpox
- 5.13.15 SARS
- 5.13.16 Rabies
- 5.13.17 Tuberculosis
- 5.13.18 Avian Flu
- 5.13.19 West Nile Virus
- 5.13.20 Herpes Simplex Virus Type-2
- 5.14 Infant Jaundice
- 5.15 Anthrax
- 5.16 Homeland Defense
- 5.17 BSE (Mad Cow Disease)
- 5.18 Tuberculosis
- 5.19 Typhoid
- 5.20 Avian flu
- 5.21 Food Pathogens (Salmonella, Listeria, Campylobacter)
- 5.22 Ruptured Fetal Membranes (ROM)
- 5.1 Blood Glucose Monitoring
- 6. POCT: Growth Regulators
- 6.1 Moderators of Growth
- 6.2 Personnel Acceptance
- 6.3 Key People for POCT
- 6.4 Information Management Issues
- 6.4.1 Elements of Information Management for POCT: Information Processing Capabilities
- 6.4.2 Data Mining
- 6.4.3 Middleware
- 6.4.4 Web Portals
- 6.4.5 POCT-1A Standard
- 6.5 Key Elements for POCT
- 6.6 POCT and Reimbursement
- 6.7 Effectiveness of Clinical Outcomes
- 6.8 Rapid Near-Patient Testing in Hospitals
- 6.9 Satellite Facilities
- 6.10 Regionalization of Laboratory Care
- 6.11 Requirements for POCT
- 6.12 Locations of Point of Care for Patient Care
- 6.13 Benefits of POCT
- 6.14 TAT for POCT
- 6.15 Clinical Laboratory Improvement Amendments (CLIA)
- 6.16 Sexually-Transmitted Diseases in Underdeveloped Countries
- 7. Business Trends in the Point of Care Sector
- 7.1 Sector Consolidation
- 7.2 Diagnostic Testing Growth Trends
- 7.3 Acquisition, License Agreements, Internal Development and Partnerships
- 7.4 Product Testing Depth in POCT
- 7.5 Government Regulation
- 7.5.1 U.S. Regulation
- 7.5.1.1 Importing Medical Devices into the U.S.
- 7.5.1.2 Exporting Medical Devices from the U.S.
- 7.5.2 U.K. Regulation
- 7.5.3 E.U. Regulation
- 7.5.3.1 French Regulation
- 7.5.4 Japanese Regulation
- 7.5.5 Korean Regulation
- 7.5.1 U.S. Regulation
- 7.6 Increased Market Penetration
- 7.7 Costs of Doing Business in Europe
- 7.8 Drivers of European Diagnostics Testing
- 7.9 European Reimbursement Practices
- 7.10 Cost Containment in Europe
- 8. Technology Platform Innovations in POCT
- 8.1 Sensor Systems for Diagnostic Applications
- 8.2 Glucose Measurements
- 8.3 Glucose Test Methods
- 8.4 Cholesterol Testing
- 8.5 The New Paradigm
- 8.6 Consolidated Workstations and Modularity
- 8.7 Automation and Robotics in the Clinical Laboratory
- 8.8 Laboratory Information Systems (LIS)
- 8.8.1 NOVIUS Lab
- 8.9 Biosensor Technology
- 9. Data Management and Connectivity
- 9.1 Wireless LANs
- 9.2 Connectivity Platforms
- 9.2.1 DataLink Data Management System
- 9.2.2 RALS-Plus
- 9.2.3 LabPortal.com
- 9.2.4 BD.id
- 9.3 Advantages of POCT Connectivity
- 9.3.1 Cost Benefit of POCT and IT Connectivity
- 10. Corporate Profiles
- 10.1 Abaxis, Inc.
- 10.2 Abbott Diagnostics
- 10.3 Accumetrics, Inc.
- 10.4 Accurex Biomedical, Pvt., Ltd.
- 10.5 Adeza Biomedical Corporation
- 10.6 Akers Biosciences
- 10.7 Ambri, Ltd.
- 10.8 American Biogenetic Sciences, Inc.
- 10.9 American Bio Medica Corp.
- 10.10 Ani Biotech
- 10.11 Apogent Technologies
- 10.12 Ark Therapeutics
- 10.13 ARKRAY
- 10.14 Atlas Genetics
- 10.15 Atonomics
- 10.16 Avitar, Inc.
- 10.17 Avox Systems
- 10.18 Axis-Shield
- 10.19 Siemens Corporation
- 10.20 Beckman Coulter
- 10.21 Binax Corporation
- 10.22 Biomerica
- 10.23 BioMérieux Vitek, Inc.
- 10.24 BioScan Screening Systems, Inc.
- 10.25 Biosite Diagnostics
- 10.26 BioStar
- 10.27 British Biocell Holdings
- 10.28 Caliper Life Sciences
- 10.29 Calypte Biomedical
- 10.30 Cardiovascular Diagnostics
- 10.31 Chembio Diagnostics
- 10.32 ChemTrak
- 10.33 Cholestech
- 10.34 Chongqing Sungene Pharmaceutical Co., Ltd.
- 10.35 CompuCyte Corporation
- 10.36 Cortech Diagnostics Ltd. (now called Kent International Holdings)
- 10.37 Cozart Biosciences
- 10.38 Cygnus Therapeutic Systems
- 10.39 Cytogen
- 10.40 Dade Behring
- 10.41 Daiichi Co., Ltd.
- 10.42 Denka Seiken Co., Ltd.
- 10.43 Diagnostic Chemicals, Ltd.
- 10.44 Enterix, Inc.
- 10.45 First Medical, Inc.
- 10.46 Focus Diagnostics, Inc.
- 10.47 GDS Technology
- 10.48 GenBio
- 10.49 Genzyme Diagnostics
- 10.50 Grant Life Sciences
- 10.51 Gryphus Diagnostics
- 10.52 Helena Laboratories
- 10.53 Hema Diagnostic Systems
- 10.54 Hemocue, Inc.
- 10.55 Home Access Health Corp.
- 10.56 i-STAT Corporation
- 10.57 Instrumentation Laboratory
- 10.58 International Medical Innovations
- 10.59 Inverness Medical Innovations
- 10.60 Immunoscience, Inc.
- 10.61 Johnson & Johnson
- 10.62 Kyowa Medex Co., Ltd.
- 10.63 LifeAssays
- 10.64 LifePoint, Inc.
- 10.65 LifeScan Corporation
- 10.66 Lifestream Technologies
- 10.67 LXN Corp. (Inverness Medical Technologies)
- 10.68 Matritech
- 10.69 Medical Services International, Inc.
- 10.70 MediSense
- 10.71 Medisys
- 10.72 Medix Biochemica
- 10.73 MedMira Laboratories
- 10.74 Meretek Corporation
- 10.75 Meridian Bioscience
- 10.76 MiniMed
- 10.77 Mitsubishi Chemical USA, Inc.
- 10.78 Mitsubishi Kagaku Iatron
- 10.79 Nanogen
- 10.80 New Horizons Diagnostics
- 10.81 Nova Biomedical
- 10.82 Väsamed, Inc.
- 10.83 OraSure
- 10.84 Orgenics
- 10.85 Orion Diagnostica
- 10.86 PanBio, Ltd.
- 10.87 PharmaNetics, Inc.
- 10.88 Phamatech, Inc.
- 10.89 Royal Philips Electronics
- 10.90 Polymedco
- 10.91 Polymer Technology Systems
- 10.92 Princeton BioMeditech Corporation
- 10.93 Quest Diagnostics
- 10.94 Quidel
- 10.95 Radiometer
- 10.96 Response Biomedical Corp.
- 10.97 Roche Diagnostics
- 10.98 StatSure Diagnostic Systems
- 10.99 Savyon Diagnostics
- 10.100 Selfcare, Inc.
- 10.101 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)
- 10.102 Shionogi & Co., Ltd.
- 10.103 SpectRx, Inc.
- 10.104 Spectral Diagnostics
- 10.105 STC Technologies
- 10.106 Strategic Diagnostics
- 10.107 Sun Biomedical Laboratories
- 10.108 Sybron International Corporation
- 10.109 TCPI
- 10.110 Therasense, Inc.
- 10.111 Thermo Biostar
- 10.112 Thoratec/International Technidyne Corp.
- 10.113 Transmedica
- 10.114 Trinity Biotech
- 10.115 Venkateshwara Hatcheries Pvt., Ltd.
- 10.116 Wampole Laboratories
- 10.117 Worldwide Medical Corporation
- 11. POCT Sector Trends and Forecasts
- 11.1 Home Care Analysis as Part of Near-Patient Testing
- 11.2 Non-Traditional Collection for POCT
- 11.3 New Systems for Critical Care and Near-Patient Testing
- 11.4 Utility of Near-Patient Testing in Critical Care Settings
- 11.5 Physician' s Office Market
- 11.6 Information Management Advances
- 11.7 Test-Ordering Patterns and Demand for POCT
- 11.8 Demand for Emergency Department Services
- 11.9 Move Away From Central Laboratory
- 11.10 Healthcare Cost Controls
- 11.11 M&A in POCT
- 11.12 Competition for Services
- 11.13 Drivers of POCT
- 11.14 Confluence of New Technology
- 11.15 Difficulties of Design for POC Products
- 11.16 European Hospital Structure
- 11.17 The Biggest New Opportunities in Point of Care Testing
- 12. Corporate Directory
LIST OF FIGURES
- Figure 3.1: Worldwide Distribution of IVD Testing in 2006
- Figure 3.2: Global Point of Care Revenues, 1998 - 2008
- Figure 3.3: Global Point of Care Testing Share of Total In Vitro Diagnostic Testing Market
- Figure 4.1 Number of HbA1c Tests Performed Globally as POCT (in Millions)
- Figure 6.1: Annual Rate of Emergency Room Visits By Primary Expected Source of Payment: U.S., 2004
INDEX OF TABLES
- Table 2.1: POC Testing
- Table 3.1: Number of ER Visits in U.S. Hospitals, 1997-2004
- Table 3.2: Number of Point of Care Tests in U.S., 2000-2012
- Table 3.3: Global Clinical Laboratory Market Sales, 1998-2010
- Table 3.4: The Overall In Vitro Diagnostic Testing Market Worldwide in 2006
- Table 3.5: Worldwide Distribution of IVD Testing in 2006
- Table 3.6: Top Twelve Country IVD Testing Markets, 2005
- Table 3.7: Fifteen Largest Diagnostic Companies Worldwide, 2005
- Table 3.8: Global Point of Care Revenues, 2000-2012
- Table 3.9: Worldwide POCT Market Size by Geographic Location, 2000 - 2012
- Table 3.10: Worldwide Distribution of POCT, 2007
- Table 3.11: Worldwide POCT by Performance Location, 2007
- Table 3.12: Worldwide Clinical Diagnostic POCT and Rapid Test Market Segments, 2007
- Table 3.13: U.S. Clinical Laboratory Testing Market, 2003-2012
- Table 3.14: U.S. Clinical Laboratory Diagnostic Test Market Segments by Location of Analysis, 2006
- Table 3.15: U.S. POCT Market, 2000-2012
- Table 3.16: U.S. POCT by Performance Location, 2007
- Table 3.17: U.S. Clinical Diagnostic POCT and Rapid Test Market Segments, 2005
- Table 3.18: European Clinical Laboratory Testing IVD Reagents and Instruments Market ($), 2000-2012
- Table 3.19: European Clinical Laboratory Testing IVD Reagents and Instruments Market (€), 2000-2012
- Table 3.20: European Clinical Laboratory Testing Diagnostics by Country Market Estimates, 2006
- Table 3.21: European Rapid Point of Care Testing by Country Market Estimates, 2006
- Table 3.22: Regional Comparison of Healthcare Spending for IVD for Eastern Europe
- Table 3.23: European POCT Market, 2000-2012
- Table 3.24: Top Twelve Country IVD and POC Testing Markets, 2005
- Table 3.25: German Clinical Laboratory Testing Diagnostics Products Market Sales, 2003-2012
- Table 3.26: German POCT Diagnostics Products Market Sales, 2003-2012
- Table 3.27: German Clinical Diagnostic Rapid Test Market Segments, 2006
- Table 3.28: U.K. Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.29: U.K. POCT Diagnostics Products Market Sales, 2006-2012
- Table 3.30: U.K. Clinical Diagnostic Rapid Test Market Segments, 2006
- Table 3.31: Major U.K. IVD Manufacturers
- Table 3.32: U.S. IVD Manufacturers Doing Business in the U.K.
- Table 3.33: Other European Companies that Manufacture IVD Products in the U.K.
- Table 3.34: French Clinical IVD Testing Diagnostics Products Market Sales, 2003-2012
- Table 3.35: French POC Diagnostics Products Market Sales, 2005-2012
- Table 3.36: French Clinical Diagnostic Rapid Test Market Segments, 2006
- Table 3.37: Italian Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.38: Italian POC Diagnostics Products Market Sales, 2005-2012
- Table 3.39: Italian Clinical Diagnostic Rapid Test Market Segments, 2006
- Table 3.40: Spanish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.41: Spanish Clinical Diagnostic Rapid Test Market Segments, 2006
- Table 3.42: Spanish POC Diagnostics Products Market Sales, 2005-2012
- Table 3.43: Scandinavian POCT Diagnostics Products Market Sales, 2000-2012
- Table 3.44: Swedish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.45: Swedish POC Diagnostics Products Market Sales, 2005-2012
- Table 3.46: Finnish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.47: Finnish POC Diagnostics Products Market Sales, 2005-2012
- Table 3.48: Norwegian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.49: Norwegian POC Diagnostics Products Market Sales, 2005-2012
- Table 3.50: Swiss Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.51: Swiss POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.52: Dutch Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.53: Dutch POC Diagnostics Products Market Sales, 2005-2012
- Table 3.54: Belgium Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.55: Belgium POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.56: Portuguese Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.57: Portuguese POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.58: Austrian Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.59: Austrian POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.60: Greek Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.61: Greek POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.62: Polish Clinical Laboratory Diagnostics Products Market Sales, 2003-2012
- Table 3.63: Polish POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.64: Czech Clinical Laboratory Diagnostics Products Market Sales, 2004-2012
- Table 3.65: Czech POCT Diagnostics Products Market Sales, 2005-2012
- Table 3.66: Turkish POCT Market, 2000-2012
- Table 3.67: Japan Point of Care Testing Market, 2000-2012
- Table 3.68: Japanese Population and Aging Demographics Forecast, 2000-2050
- Table 3.69: Indian IVD Market for Instruments and Reagents, 2004-2012
- Table 3.70: Number of Automated Clinical Labs in India, 2004-2012
- Table 3.71: Indian IVD Market, 2006
- Table 3.72: Indian Point of Care Diagnostics Products Market Sales, 2000-2008
- Table 3.73: Chinese IVD Market, 2006-2012
- Table 3.74: Number of Automated Clinical Labs in China, 2004-2012
- Table 3.75: Chinese IVD Market, 2006
- Table 3.76: Chinese Point of Care Diagnostics Products Market Sales, 2000-2012
- Table 3.77: The Rest of the World POCT Market, 2000-2012
- Table 3.78: Canadian POCT Market, 2000-2012
- Table 3.79: Brazilian POCT Market, 2000-2012
- Table 3.80: Australian POCT Market, 2000-2012
- Table 4.1: World Market Share of Point of Care Glucose Monitoring Marketers
- Table 4.2: The Global Population of Persons with Diabetes, 1995 and 2025
- Table 4.3: The Glucose Testing Market for POCT Worldwide, 2001-2012
- Table 4.4: U.S. Point of Care Glucose Testing Market, 1997-2012
- Table 4.5: Manufacturer Market Share U.S. POCT Market, 2007
- Table 4.6: Rapid Testing U.S. Market Share for Blood Glucose Testing Segment
- Table 4.7: The HbA1c Testing Market for POCT Worldwide, 2006-2012
- Table 4.8: The Critical Care Blood Gas Testing Market for POCT Worldwide, 2006-2012
- Table 4.9: The Blood Gas and Electrolyte Market for POCT in the U.S., 2001-2012
- Table 4.10: Location Market Share of Critical Care Blood Gas Testing
- Table 4.11: Manufacturer Market Share U.S. POCT Blood Gas and Electrolytes Market, 2005
- Table 4.12: The Coagulation Testing Market for POCT Worldwide, 2006-2012
- Table 4.13: The Hand-held Coagulation Testing Market for POCT Worldwide, 2006-2012
- Table 4.14: The Coagulation Market for POCT in the U.S., 2001-2012
- Table 4.15: The POC Prothrombin Market for POCT in the U.S., 2000-2007
- Table 4.16: The Cardiac Marker Market for POCT in the U.S., 2001-2012
- Table 4.17: The Cardiac Marker Market for POCT Worldwide, 2001-2012
- Table 4.18: Manufacturer Market Share U.S. POCT Cardiac Marker Market, 2005
- Table 4.19: The Cardiac Marker Market for POCT in Europe, 2001-2011
- Table 4.20: Drugs of Abuse Testing Market for POCT Worldwide, 2006-2012
- Table 4.21: U.S. Point of Care Drugs of Abuse Testing Market, 2006-2012
- Table 4.22: Drug Testing Needs Tier 1 for Rapid Serum Point of Care Testing in the Emergency Department
- Table 4.23: Stat Urine Testing Drug Recommendations
- Table 4.24: Device Specifications for POC Breath Alcohol Analysis
- Table 4.25: Global Point of Care Urine Test Strip Testing Market, 2001-2007
- Table 4.26: Global Point of Care Urine Test Strip POCT Testing Market, 2006-2012
- Table 4.27: U.S. Point of Care Urine Test Strip Testing Market, 2001-2011
- Table 4.28: U.S. Point of Care Urine Test Strip Testing Market Share
- Table 4.29: Medicare Fee Schedule for Urine Chemistry Testing
- Table 4.30: Pregnancy Testing Market for POCT Worldwide, 2006-2012
- Table 4.31: U.S. Point of Care Pregnancy Testing Market, 2001-2012
- Table 4.32: International Point of Care Pregnancy Testing Markets, 2001-2007
- Table 4.33: U.S. Market Share for Rapid Point of Care Pregnancy Tests
- Table 4.34: Hemoglobin Testing Market for POCT Worldwide, 2006-2012
- Table 4.35: Worldwide POCT Market for HIV, 2001-2012
- Table 4.36: U.S. POCT Market for HIV, 2001-2012
- Table 4.37: Countries with the Highest Prevalence of HIV/AIDS
- Table 4.38: FDA-Approved Rapid HIV Antibody Screening Tests
- Table 4.39: OraSure OraQuick Rapid HIV Test Revenues, 2005
- Table 4.40: The Cholesterol Testing Market for POCT Worldwide, 2006-2012
- Table 4.41: The Infectious Disease Testing Market for POCT Worldwide, 2006-2012
- Table 4.42: Salmonella Testing Market, 2002-2007
- Table 4.43: Worldwide Point of Care Influenza Testing Market, 2002-2007
- Table 4.44: U.S. Point of Care Influenza Testing Market, 2002-2007
- Table 4.45: International Point of Care Influenza Testing Markets, 2002-2007
- Table 4.46: U.S. Market for Rapid Point of Care Influenza Tests, 2005
- Table 4.47: Worldwide Point of Care Strep A Testing Market, 2002-2007
- Table 4.48: U.S. Point of Care Strep A Testing Market, 2002-2007
- Table 4.49: International Point of Care Strep A Testing Markets, 2002-2007
- Table 4.50: U.S. Market for Rapid Point of Care for Group A Strep Tests
- Table 4.51: Global Market for Chlamydia Diagnostic Testing, 2000-2009
- Table 4.52: U.S. Market for Chlamydia Diagnostic Testing, 2000-2009
- Table 4.53: Global Market for Gonorrhea Diagnostic Testing, 2000-2009
- Table 4.54: Global Market for TB Diagnostic Testing, 2000-2008
- Table 4.55: U.S. Anthrax Test Market
- Table 5.1: Drug Test Sensitivity Cut-Off Levels Established as Standard by NIDA, WHO and SAMHSA for Drugs of Abuse
- Table 5.2: Major Competitors in the Drugs of Abuse Testing Market Segment
- Table 5.3: Major Competitors in the Drugs of Abuse Oral Testing Market Segment
- Table 5.4: Major Competitors in the Drugs of Abuse Urine Testing Market Segment
- Table 5.5: Major Competitors in the Drugs of Abuse Saliva Testing Market Segment
- Table 5.6 Siemens Urinalysis Near-patient Devices
- Table 5.7: ColoCARE Fecal Occult Blood Test
- Table 5.8: Type of Hepatitis Test: Lateral Flow
- Table 5.9: Flow-Through
- Table 5.10: Agglutination
- Table 5.11: Immunoblot
- Table 5.12: AmniSure
- Table 6.1: Access Points
- Table 6.2: Desktop Adapters-One Computer
- Table 6.3: Desktop Adapters-Four Computers
- Table 6.4: PCMCIA Adapters
- Table 6.5: POCT1-Compliant Connectivity Point of Care Instruments
- Table 6.6: POCT Clinical Outcomes in Diabetic Ketoacidosis
- Table 6.7: POCT Clinical Outcomes in Arterial Blood Gas Measurements
- Table 6.8: POCT in Three Hospitals. Cost Analysis with Labor Included
- Table 6.9: Cost Analysis for Glucose Testing: POCT vs. Central Lab
- Table 6.10: Financial Comparison for Moderate and Waived CLIA Labs
- Table 7.1 Key Changes in IVD Business Structure
- Table 7.2 Business Trends in Point of Care Testing
- Table 7.3 Key Players Bring Business Developments to Point of Care Diagnostic Testing
- Table 8.1: Normal Glucose Values-Fasting State
- Table 9.1: Applications for Wireless LAN Technology
- Table 9.2: Wireless LAN Technology Companies
- Table 9.3: Customized Reports Must Support CAP and JCAHO Requirements
- Table 9.4 RALS-Plus Point of Care Market Share
- Table 9.5: Applications of RALS Connectivity with POCT Devices
- Table 10.1: Products Marketed by Abbott in the Diagnostic Market
- Table 10.2: Quidel Product Sales Distribution and Sales, 2006
- Table 11.1: Improvements in Achieving ED Operational Efficiency Using POCT
- Table 11.2: Test Menu and TAT for ED
- Table 11.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED
- Table 11.4: Key Areas and Metrics That Hospitals Measure To Assess Efficiency of ED
- Table 11.5: Estimates of Patient Costs by DRG
